vs
ARTIVION, INC.（AORT）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
GIBRALTAR INDUSTRIES, INC.的季度营收约是ARTIVION, INC.的1.9倍（$225.0M vs $116.0M），GIBRALTAR INDUSTRIES, INC.同比增速更快（24.9% vs 19.2%），GIBRALTAR INDUSTRIES, INC.自由现金流更多（$26.2M vs $-7.9M），过去两年ARTIVION, INC.的营收复合增速更高（9.1% vs -12.3%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
AORT vs ROCK — 直观对比
营收规模更大
ROCK
是对方的1.9倍
$116.0M
营收增速更快
ROCK
高出5.7%
19.2%
自由现金流更多
ROCK
多$34.2M
$-7.9M
两年增速更快
AORT
近两年复合增速
-12.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $225.0M |
| 净利润 | $2.4M | — |
| 毛利率 | 63.1% | 25.3% |
| 营业利润率 | 9.2% | 7.9% |
| 净利率 | 2.1% | — |
| 营收同比 | 19.2% | 24.9% |
| 净利润同比 | 114.7% | — |
| 每股收益（稀释后） | $0.06 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTROCK
| Q4 25 | $116.0M | $225.0M | ||
| Q3 25 | $113.4M | $310.9M | ||
| Q2 25 | $113.0M | $309.5M | ||
| Q1 25 | $99.0M | $290.0M | ||
| Q4 24 | $97.3M | $180.1M | ||
| Q3 24 | $95.8M | $277.1M | ||
| Q2 24 | $98.0M | $273.6M | ||
| Q1 24 | $97.4M | $292.5M |
净利润AORTROCK
| Q4 25 | $2.4M | — | ||
| Q3 25 | $6.5M | $-89.1M | ||
| Q2 25 | $1.3M | $26.0M | ||
| Q1 25 | $-505.0K | $21.1M | ||
| Q4 24 | $-16.5M | — | ||
| Q3 24 | $-2.3M | $34.0M | ||
| Q2 24 | $-2.1M | $32.2M | ||
| Q1 24 | $7.5M | $24.9M |
毛利率AORTROCK
| Q4 25 | 63.1% | 25.3% | ||
| Q3 25 | 65.6% | 26.6% | ||
| Q2 25 | 64.7% | 28.4% | ||
| Q1 25 | 64.2% | 26.8% | ||
| Q4 24 | 63.2% | 29.0% | ||
| Q3 24 | 63.7% | 29.4% | ||
| Q2 24 | 64.6% | 30.5% | ||
| Q1 24 | 64.6% | 28.9% |
营业利润率AORTROCK
| Q4 25 | 9.2% | 7.9% | ||
| Q3 25 | 11.1% | 12.8% | ||
| Q2 25 | 7.4% | 12.8% | ||
| Q1 25 | 2.2% | 8.8% | ||
| Q4 24 | 2.7% | 13.3% | ||
| Q3 24 | 4.6% | 15.6% | ||
| Q2 24 | 6.6% | 14.9% | ||
| Q1 24 | 26.0% | 10.8% |
净利率AORTROCK
| Q4 25 | 2.1% | — | ||
| Q3 25 | 5.7% | -28.6% | ||
| Q2 25 | 1.2% | 8.4% | ||
| Q1 25 | -0.5% | 7.3% | ||
| Q4 24 | -16.9% | — | ||
| Q3 24 | -2.4% | 12.3% | ||
| Q2 24 | -2.2% | 11.8% | ||
| Q1 24 | 7.7% | 8.5% |
每股收益（稀释后）AORTROCK
| Q4 25 | $0.06 | — | ||
| Q3 25 | $0.13 | $-2.98 | ||
| Q2 25 | $0.03 | $0.87 | ||
| Q1 25 | $-0.01 | — | ||
| Q4 24 | $-0.40 | — | ||
| Q3 24 | $-0.05 | $1.11 | ||
| Q2 24 | $-0.05 | $1.05 | ||
| Q1 24 | $0.18 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $115.7M |
| 总债务越低越好 | $215.1M | $0 |
| 股东权益账面价值 | $448.2M | $950.4M |
| 总资产 | $884.8M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资AORTROCK
| Q4 25 | $64.9M | $115.7M | ||
| Q3 25 | $73.4M | $89.4M | ||
| Q2 25 | $53.5M | $43.3M | ||
| Q1 25 | $37.7M | $25.1M | ||
| Q4 24 | $53.5M | $269.5M | ||
| Q3 24 | $56.2M | $228.9M | ||
| Q2 24 | $55.0M | $179.1M | ||
| Q1 24 | $51.1M | $146.7M |
总债务AORTROCK
| Q4 25 | $215.1M | $0 | ||
| Q3 25 | $214.9M | $0 | ||
| Q2 25 | $215.6M | $0 | ||
| Q1 25 | $314.7M | $0 | ||
| Q4 24 | $314.3M | $0 | ||
| Q3 24 | $314.0M | $0 | ||
| Q2 24 | $313.6M | $0 | ||
| Q1 24 | $313.3M | $0 |
股东权益AORTROCK
| Q4 25 | $448.2M | $950.4M | ||
| Q3 25 | $438.7M | $951.8M | ||
| Q2 25 | $419.9M | $1.0B | ||
| Q1 25 | $294.3M | $1.0B | ||
| Q4 24 | $276.2M | $1.0B | ||
| Q3 24 | $304.7M | $1.0B | ||
| Q2 24 | $295.1M | $975.7M | ||
| Q1 24 | $295.0M | $940.2M |
总资产AORTROCK
| Q4 25 | $884.8M | $1.4B | ||
| Q3 25 | $857.7M | $1.4B | ||
| Q2 25 | $838.4M | $1.5B | ||
| Q1 25 | $791.2M | $1.4B | ||
| Q4 24 | $789.1M | $1.4B | ||
| Q3 24 | $803.1M | $1.4B | ||
| Q2 24 | $789.5M | $1.4B | ||
| Q1 24 | $784.0M | $1.3B |
负债/权益比AORTROCK
| Q4 25 | 0.48× | 0.00× | ||
| Q3 25 | 0.49× | 0.00× | ||
| Q2 25 | 0.51× | 0.00× | ||
| Q1 25 | 1.07× | 0.00× | ||
| Q4 24 | 1.14× | 0.00× | ||
| Q3 24 | 1.03× | 0.00× | ||
| Q2 24 | 1.06× | 0.00× | ||
| Q1 24 | 1.06× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $26.2M |
| 自由现金流率自由现金流/营收 | -6.9% | 11.7% |
| 资本支出强度资本支出/营收 | 23.7% | 4.1% |
| 现金转化率经营现金流/净利润 | 8.06× | — |
| 过去12个月自由现金流最近4个季度 | $839.0K | $120.6M |
8季度趋势，按日历期对齐
经营现金流AORTROCK
| Q4 25 | $19.6M | $35.5M | ||
| Q3 25 | $22.3M | $73.0M | ||
| Q2 25 | $15.0M | $44.9M | ||
| Q1 25 | $-17.0M | $13.7M | ||
| Q4 24 | $10.1M | $19.9M | ||
| Q3 24 | $11.5M | $64.7M | ||
| Q2 24 | $6.1M | $36.5M | ||
| Q1 24 | $-5.5M | $53.2M |
自由现金流AORTROCK
| Q4 25 | $-7.9M | $26.2M | ||
| Q3 25 | $17.7M | $64.8M | ||
| Q2 25 | $11.7M | $27.3M | ||
| Q1 25 | $-20.6M | $2.3M | ||
| Q4 24 | $8.7M | $14.1M | ||
| Q3 24 | $7.8M | $60.5M | ||
| Q2 24 | $3.6M | $33.5M | ||
| Q1 24 | $-9.1M | $48.8M |
自由现金流率AORTROCK
| Q4 25 | -6.9% | 11.7% | ||
| Q3 25 | 15.6% | 20.8% | ||
| Q2 25 | 10.4% | 8.8% | ||
| Q1 25 | -20.8% | 0.8% | ||
| Q4 24 | 9.0% | 7.8% | ||
| Q3 24 | 8.2% | 21.8% | ||
| Q2 24 | 3.7% | 12.2% | ||
| Q1 24 | -9.3% | 16.7% |
资本支出强度AORTROCK
| Q4 25 | 23.7% | 4.1% | ||
| Q3 25 | 4.1% | 2.6% | ||
| Q2 25 | 2.9% | 5.7% | ||
| Q1 25 | 3.7% | 3.9% | ||
| Q4 24 | 1.5% | 3.3% | ||
| Q3 24 | 3.8% | 1.5% | ||
| Q2 24 | 2.6% | 1.1% | ||
| Q1 24 | 3.7% | 1.5% |
现金转化率AORTROCK
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | — | ||
| Q2 25 | 11.16× | 1.73× | ||
| Q1 25 | — | 0.65× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | -0.73× | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
